Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Murthy RK, et al. Among authors: fujii t. Clin Breast Cancer. 2018 Dec;18(6):e1283-e1288. doi: 10.1016/j.clbc.2018.07.008. Epub 2018 Jul 10. Clin Breast Cancer. 2018. PMID: 30077429 Clinical Trial.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Kogawa T, et al. Among authors: fujii t. Oncologist. 2020 Jun;25(6):e909-e919. doi: 10.1634/theoncologist.2018-0611. Epub 2020 Jan 31. Oncologist. 2020. PMID: 32003919 Free PMC article.
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.
Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Kogawa T, et al. Among authors: fujii t. J Cancer. 2015 Jan 22;6(4):310-8. doi: 10.7150/jca.10580. eCollection 2015. J Cancer. 2015. PMID: 25767600 Free PMC article.
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. Kogawa T, et al. Among authors: fujii t. Oncologist. 2016 Jan;21(1):21-7. doi: 10.1634/theoncologist.2015-0101. Epub 2015 Dec 9. Oncologist. 2016. PMID: 26659222 Free PMC article.
Impact of clinical trial on survival outcomes.
Le Du F, Fujii T, Park M, Liu D, Hsu L, Gonzalez-Angulo AM, Ueno NT. Le Du F, et al. Among authors: fujii t. Breast Cancer Res Treat. 2016 Sep;159(2):273-81. doi: 10.1007/s10549-016-3942-5. Epub 2016 Aug 16. Breast Cancer Res Treat. 2016. PMID: 27530453
6,359 results